Our proprietary mAb generation platform encompasses immunogen design, immunization, high-efficient fusion, and high-throughput screening (HTS), enabling the effective generation of functional mAbs that bind novel targets or known antigens with high affinity and specificity. 

The in vivo-matured antibodies typically exhibit nanomolar-range binding affinities and strong developability profiles. Combined with our specialized antibody engineering process, our antibody candidates can be seamlessly advanced into downstream production for preclinical and clinical development.